FDA approves oral dermatomyositis therapy

• by Kathryn Wighton

• August 28, 2026

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

• by Kathryn Wighton

• April 28, 2026

• 2 min

Facial Hemangiomas May Signal PHACE

Early recognition of segmental facial lesions prompted diagnosis and multidisciplinary care in an infant with multisystem involvement

• by Andrea Surnit

• April 14, 2026

• 3 min

Cutaneous Rhabdomyosarcoma May Mask Melanoma

Molecular and epigenetic profiling suggested most tumors in a rare cutaneous sarcoma cohort were better classified as transdifferentiated melanoma.

• by Andrea Surnit

• April 28, 2026

• 3 min